Stockreport

SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium [Yahoo! Finance]

Scienture Holdings, Inc.  (SCNX) 
PDF Outlines Q1 2026 outlook and reports significant balance sheet improvement last quarter COMMACK, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDA [Read more]